Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy
Open Access
- 2 June 2020
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 40 (6) , 3361-3370
Abstract
Background/Aim: We evaluated whether splenic volume (SV) predicts sinusoidal obstruction syndrome (SOS) in colorectal cancer (CRC) patients receiving capecitabine plus oxaliplatin (CapeOX) therapy. Patients and Methods: In this retrospective study, we measured SV in 41 patients receiving adjuvant CapeOX for CRC at five different time points. We compared the clinical data of the 18 patients who experienced ≥30% increases in SV immediately after vs. before CapeOX (group A) with data for the remaining 23 patients (group B). Results: Platelet numbers decreased and the levels of hepatobiliary enzymes increased significantly 1 year after CapeOX compared with before CapeOX in group A. However, in group B, significantly decreased platelet numbers and significantly increased aspartate transaminase levels were confirmed only immediately after CapeOX, with no significant subsequent changes. Conclusion: SV was significantly associated with thrombocytopenia and liver dysfunction in CRC patients, and predicted SOS.Keywords
This publication has 18 references indexed in Scilit:
- Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapyClinical Journal of Gastroenterology, 2018
- Oxaliplatin‐induced increase in splenic volume; irreversible change after adjuvant FOLFOXJournal of Surgical Oncology, 2017
- Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During ChemotherapyMedicine, 2016
- Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndromeEuropean Journal of Surgical Oncology, 2014
- Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastasesHistopathology, 2012
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative ChemotherapyAnnals of Surgery, 2008
- Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastasesCancer, 2007
- Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerAnnals of Oncology, 2004
- Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantationBone Marrow Transplantation, 2001